K-numberK250353
Device nameOniris; Oniris Plus
ApplicantOniris
Product codeLRK
Device classClass II
Decision dateSep 4, 2025
DecisionSubstantially Equivalent
Regulation872.5570
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

Oniris and Oniris Plus are intraoral mandibular advancement devices designed to reduce snoring and treat mild-to-moderate obstructive sleep apnea in adults. Each device consists of two independent splints (upper and lower trays) custom-fitted at home using a boil-and-bite process, connected by interchangeable advancement hooks that allow mandibular protrusion of up to 6mm (OTC) or 11mm (Rx).

Technological characteristics

Both subject and predicate devices are mandibular advancement appliances with upper and lower trays made from rigid outer shells with moldable material, customized through boil-and-bite at home. The main difference is in hook attachment: Oniris features an enlarged stopper on the lower tray with an integrated slot for secure attachment via applied pressure and angular rotation, plus a key-like locking system on the upper tray, whereas SmartGuard uses only applied pressure on both trays.

Test standards cited

No FDA-recognized consensus standards or guidance documents were specifically cited. Testing was based on internal product specifications and predicate device comparison, using calibrated precision instruments (caliper and scale) with traceability to international standards (Calibration Certificates: FACOM CK311539, RS PRO JS-10).

Substantial equivalence argument

The subject devices share the same indications for use and mandibular advancement principle as the predicate SmartGuard. Nonclinical bench testing confirmed dimensional conformity, comparable tray geometry, hook function, transparency, and packaging to the predicate. Although Oniris devices are slightly larger and feature improved hook attachment mechanisms (enlarged stopper and key-like locking), these design refinements enhance stability and usability without affecting safety or effectiveness, and comparative testing demonstrated the dimensional differences do not impact intended use or target patient population.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →